Analysts Set STAAR Surgical (NASDAQ:STAA) Target Price at $42.83

As of December 15, 2024, STAAR Surgical (NASDAQ:STAA) has received an average recommendation of "Hold" from nine brokerages currently covering the company, according to Marketbeat Ratings. Among these analysts, one issued a sell rating, four assigned a hold rating, and four rated the stock as a buy. The average target price set by these brokerages for STAAR Surgical over the next 12 months is $42.83.

Recent comments from various equity research analysts highlight shifting opinions on STAAR's share price. Canaccord Genuity Group adjusted their price target for STAAR Surgical, moving it down from $31.00 to $28.00 while maintaining a "hold" rating in a report issued on December 9. Needham & Company reaffirmed a "hold" rating on the stock in a note released on October 31. Stifel Nicolaus reduced their price target from $50.00 to $44.00 and kept a "buy" rating in a report dated August 26. Additionally, Stephens upgraded the shares to a "hold" rating in their research on December 2.

Performance of STAAR Surgical Stock

On Thursday, STAAR Surgical's stock opened at $24.86. The stock has experienced a one-year low of $24.21 and a high of $52.68. Currently, the company has a market capitalization of $1.23 billion, a price-to-earnings (P/E) ratio of 56.50, and a beta of 0.59. The recent 50-day moving average stands at $28.91, while the 200-day moving average is $34.97.

Institutional Investors' Involvement

Several large investors have recently changed their holdings in STAAR Surgical. For instance, Van ECK Associates Corp increased its stake by 12.7% during the third quarter, now holding 3,478 shares valued at $129,000 after acquiring 393 additional shares. Sei Investments Co. also raised its holdings by 2.7% in the second quarter, reaching 15,087 shares valued at $718,000 following a purchase of 394 more shares. Creative Planning enhanced its stake by 8.0% in the third quarter, amassing 5,524 shares valued at $205,000 after acquiring 408 shares. Wealth Enhancement Advisory Services LLC and the Louisiana State Employees Retirement System similarly increased their stakes during the second quarter. Currently, approximately 96.70% of STAAR Surgical's stock is owned by institutional investors.

Company Overview

STAAR Surgical Company, along with its subsidiaries, specializes in designing, developing, manufacturing, marketing, and selling implantable lenses for the eye and associated delivery systems for lens implantation. The company's product lineup includes implantable Collamer lenses (ICLs), which are used to address various vision disorders, including myopia, hyperopia, astigmatism, and presbyopia.

analysts, stock, price, rating, investment